Ocular therapeutix™ highlights exceptional axpaxli™ sol-1 enrollment and plans for repeat dosing study (sol-r) in wet amd at investor day, along with positive 48-week data from helios npdr study

151 subjects enrolled in various stages of loading and randomization in sol-1 pivotal study of axpaxli in wet amd as of june 7, 2024
SOL Ratings Summary
SOL Quant Ranking